Bisio Matteo, Legato Luca, Fasano Filippo, Benevolo Savelli Corrado, Boccomini Carola, Nicolosi Maura, Santambrogio Elisa, Freilone Roberto, Novo Mattia, Botto Barbara
Hematology Division, A.O.U. Città della Salute e della Scienza di Torino, C.so Bramante 88, 10126 Turin, Italy.
Cancers (Basel). 2024 Dec 31;17(1):94. doi: 10.3390/cancers17010094.
The introduction of highly active immunotherapies has changed the outcome of B-cell non-Hodgkin lymphomas (B-NHLs) in the last two decades. Since then, important progress has been shown using newer and more active immunotherapies, including chimeric antigen receptor T-cell therapy (CAR-T), conjugated monoclonal antibodies, and bispecific antobodies, which currently plays a significant role in the treatment of diffuse large B-cell (DLBCL), follicular (FL), and mantle cell (MCL) lymphoma.
In this review, we provide an updated overview of recently completed and ongoing BsAb trials in patients with relapsed/refractory(R/R) B-NHL and Hodgkin's lymphoma, including single-agent results, emerging combinations, safety data, and novel constructs.
Bispecific antibodies (BsAbs) are a novel class of "off-the-shelf" T-cell-redirecting drugs capable of targeting various cell-surface antigens. New antigen targets are currently under investigation, such as CD19 × CD3 and CD30 × CD3 or CD30 × CD16, in different settings. BsAbs are among the most promising therapeutic options for lymphoma today since they have demonstrated significant single-agent activity, along with a manageable toxicity profile, in patients with heavily pretreated B-NHL.
在过去二十年中，高活性免疫疗法的引入改变了B细胞非霍奇金淋巴瘤（B-NHL）的治疗结果。从那时起，使用更新、更有效的免疫疗法取得了重要进展，包括嵌合抗原受体T细胞疗法（CAR-T）、偶联单克隆抗体和双特异性抗体，这些疗法目前在弥漫性大B细胞淋巴瘤（DLBCL）、滤泡性淋巴瘤（FL）和套细胞淋巴瘤（MCL）的治疗中发挥着重要作用。
在本综述中，我们提供了关于复发/难治性（R/R）B-NHL和霍奇金淋巴瘤患者近期完成和正在进行的双特异性抗体（BsAb）试验的最新概述，包括单药治疗结果、新出现的联合治疗、安全性数据和新型构建体。
双特异性抗体（BsAbs）是一类新型的“现成可用”的T细胞重定向药物，能够靶向多种细胞表面抗原。目前正在不同背景下研究新的抗原靶点，如CD19×CD3、CD30×CD3或CD30×CD16。双特异性抗体是当今淋巴瘤最有前景的治疗选择之一，因为它们在经过大量预处理的B-NHL患者中已显示出显著的单药活性以及可控的毒性特征。
Zotero 插件